The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093 Jiangsu, P.R. China.
J Microbiol Biotechnol. 2013 Sep 28;23(9):1197-205. doi: 10.4014/jmb.1305.05004.
Urokinase (uPA) and its receptor (uPAR) play an important role in tumor growth and metastasis. Targeting the excessive activation of this system as well as the proliferation of the tumor vascular endothelial cell would be expected to prevent tumor neovasculature and halt the tumor development. In this regard, the amino-terminal fragment (ATF) of urokinase has been confirmed as effective to inhibit the proliferation, migration, and invasiveness of cancer cells via interrupting the interaction of uPA and uPAR. Previous studies indicated that ATF expressed in Escherichia coli was mainly contained in inclusion bodies and also lacked posttranslational modifications. In this study, the biologically active and soluble ATF was cloned and expressed in Pichia pastoris. The recombinant protein was purified to be homogenous and confirmed to be biologically active. The yield of the active ATF was about 30 mg/l of the P. pastoris culture medium. The recombinant ATF (rATF) could efficiently inhibit angiogenesis, endothelial cell migration, and tumor cell invasion in vitro. Furthermore, it could inhibit in vivo xenograft tumor growth and prolong the survival of tumor-bearing mice significantly by competing with uPA for binding to cell surfaces. Therefore, P. pastoris is a highly efficient and cost-effective expression system for large-scale production of biologically active rATFs for potential therapeutic application.
尿激酶(uPA)及其受体(uPAR)在肿瘤生长和转移中发挥着重要作用。靶向该系统的过度激活以及肿瘤血管内皮细胞的增殖,有望防止肿瘤新生血管形成并阻止肿瘤发展。在这方面,尿激酶的氨基末端片段(ATF)已被证实可通过中断 uPA 和 uPAR 的相互作用来有效抑制癌细胞的增殖、迁移和侵袭。先前的研究表明,在大肠杆菌中表达的 ATF 主要包含在包涵体中,并且还缺乏翻译后修饰。在本研究中,将具有生物活性和可溶性的 ATF 进行克隆并在毕赤酵母中表达。该重组蛋白被纯化至均质,并被证实具有生物活性。毕赤酵母培养基中具有活性的 ATF 的产量约为 30mg/L。重组 ATF(rATF)可在体外有效抑制血管生成、内皮细胞迁移和肿瘤细胞侵袭。此外,通过与 uPA 竞争与细胞表面结合,rATF 可显著抑制体内异种移植肿瘤的生长并延长荷瘤小鼠的存活时间。因此,毕赤酵母是一种高效且具有成本效益的表达系统,可大规模生产用于潜在治疗应用的具有生物活性的 rATF。